Table 4.
The univariate and multivariable analysis results for predicting mortality in patients treated with transjugular intrahepatic portosystemic shunt
| Characteristics |
Univariate analysis
|
Multivariate analysis
|
||||
|
HR
|
95%CI
|
P value
|
HR
|
95%CI
|
P value
|
|
| Age (years) | 1.042 | (1.008-1.077) | 0.016a | 1.047 | (1.012-1.084) | 0.278 |
| Gender (male) | 1.187 | (0.559-2.518) | 0.656 | |||
| BMI (kg/m2) | 1.000 | (0.871-1.148) | 0.997 | |||
| Etiology (Viral hepatitis/other) | 1.187 | (0.559-2.518) | 0.656 | |||
| Ascites (yes/no) | 1.652 | (0.714-3.823) | 0.241 | |||
| Child-Pugh score | 1.317 | (1.064-1.630) | 0.011a | 1.194 | (0.903-1.579) | 0.740 |
| MELD score | 1.089 | (1.013-1.172) | 0.021a | 1.050 | (0.963-1.146) | 0.845 |
| NLR | 1.060 | (0.994-1.130) | 0.075 | |||
| TBIL (umol/L) | 1.022 | (0.996-1.048) | 0.096 | |||
| ALT (U/L) | 1.003 | (0.986-1.020) | 0.745 | |||
| AST (U/L) | 1.007 | (0.998-1.016) | 0.109 | |||
| Reduction in PPG (%) | 1.030 | (0.992-1.069) | 0.120 | |||
| Albumin (g/L) | 0.904 | (0.836-0.977) | 0.011a | 0.903 | (0.827-0.986) | 0.023a |
| Creatinine (umol/L) | 1.012 | (1.000-1.024) | 0.044a | 1.005 | (0.993-1.018) | 0.342 |
| PMA (HU) | 0.887 | (0.839-0.938) | < 0.001a | 0.901 | (0.853-0.951) | < 0.001a |
| TPMT (mm/m) | 0.851 | (0.759-0.954) | 0.006a | 0.867 | (0.760-0.988) | 0.032a |
a
P < 0.05.
BMI: Body mass index; MELD: Model for end-stage liver disease; NLR: Neutrophil-lymphocyte ratio; TBIL: Total bilirubin; ALT: Alanine aminotransferase; AST: Aspartate transaminase; PPG: Portosystemic pressure gradient; PMA: Psoas muscle attenuation; TPMT: Transversal psoas muscle thickness; HU: Hounsfield units.